A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The anticonvulsant drug lamotrigine (LTG), a sodium channel blocker and inhibitor of glutamate release, has been found to have antidepressant effects in the treatment of bipolar disorder. It is recommended by certain therapy guidelines as a first-line agent for acute and maintenance therapy in bipolar depression, but there have been only some promising results of placebo-controlled trials on its acute antidepressant effects, and the recommendation in therapy guidelines has been reconsidered. On the contrary, positive results for maintenance therapy could be confirmed, and LTG is still a well-tolerated option, especially in patients with predominant depressive episodes. Antimanic effects are not shown in the literature, and its use is not advised in any guidelines that were examined. In conclusion, the findings of the present review article on treatment guidelines for bipolar disorder question the role of LTG in acute depressive states, and critically discusses its use, particularly in acute depressive states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative
Merikangas, K. R., Jin, R., He, J.-P., Kessler, R. C., Lee, S., Sampson, N. A., Viana, M. C., Andrade, L. H., Hu, C., Karam, E. G., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.12 · Cited by 2,627 · cited 1×
“4%.(1) Treatment of different affective conditions is challenging; distinct treatment strategies, not only for acute episodes, but also for prevention of relapse of either depression or mania are essential.”
BackgroundCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Goodwin, G. M., Bowden, C. L., Calabrese, J. R., Grunze, H., Kasper, S., White, R., Greene, P., & Leadbetter, R. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0321 · Cited by 581 · cited 1×
“120).(31) In the trial of van der Loos et al,(32) LTG was used as an add-on treatment compared to PLC in patients with bipolar 1 or 2 depression already on lithium monotherapy.”
MethodCalabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1106 · Cited by 498
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446 · cited 4×
“700).(24) In 2006, Brown et al(25) compared LTG with the combination of olanzapine/fluoxetine (OFC) in the acute treatment of bipolar 1 depression.”
BackgroundMethodResultInfluentialGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & WFSBP Task Force On Treatment Guidelines For Bipolar Disorders (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903555881 · Cited by 399
Brown, E. B., McElroy, S. L., Keck, P. E., Deldar, A., Adams, D. H., Tohen, M., & Williamson, D. J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0703 · Cited by 244
Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D., Licht, R., Vieta, E., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150612 · Cited by 185
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression
Brown, E., Dunner, D. L., McElroy, S. L., Keck, P. E., Adams, D. H., Degenhardt, E., Tohen, M., & Houston, J. P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009735 · Cited by 73
Maina, G., Albert, U., Rosso, G., & Bogetto, F. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0413 · Cited by 50
New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder
Calabrese, Jr., Rapport, D., Youngstrom, E., Jackson, K., Bilali, S., & Findling, R. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2004.12.003 · Cited by 46
Cited by
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“Lamotrigine has received considerable support from many clinicians and some controlled trials (Bowden and Singh, 2012; Reinares et al., 2013; Selle et al., 2014; Sienaert et al., 2013; Trankner et al., 2013), in the management of bipolar depression.”
BackgroundBahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Clinical practice guidelines for management of bipolar disorder
Shah, N., Grover, S., & Rao, G. (2017) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.196974 · Cited by 124
Pan, P.-Y., Lee, M.-S., Lo, M.-C., Yang, E.-L., & Yeh, C.-B. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-145 · Cited by 9
Metadata
- Authors
- Schoenknecht, P., Traenkner, & Sander
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2013-01
- Volume
- 9
- Pages
- 101
- ISSN
- 1176-6328 (ISSN-L)
- OpenAlex
- W1562663508
- Cited by
- 16
- References
- 11
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.